Unlimited shares at 13

Tell me again how this is not dilution, I'm waiting.

As if charts matter in the Pink world, LMFAO

So what do you expect here...dividend ? LMFAO any point of owning shares in this company at all ?

It looks like it might bounce from 0012 to 0005 now.

This was a gamble, a bad one, I'd rather do Casino, I do not like dead money in the water, money has to work for me and in this stock it's lazy, better pastures elsewhere, plenty stocks trending today and this one is not one of them.

If you all want to get higher you'll have to grab my shares, if not...we'll be neighbors for a while.

It's bouncing backwards, is that why nobody wants my shares at 31, I paid 34 for it, here's a discount for all of you true and loyal. I got a Bitcoin stock to catch...it's running wild while here I'm still waiting for the bus that comes once a month.

Well...it's garbage today, I might come back when is at least recyclable.

C'mon man, this stock is garbage, it's a "get in if you want, get out if you can" stock. Got plenty stocks that trade every second in this market.

I don't do long term, I eat every day not every month.

FTXP SECURITY DETAILS
Share Structure
Market Cap Market Cap
6,781,338
01/04/2022
Authorized Shares
19,975,000,000
01/03/2022
Outstanding Shares
9,687,625,597
01/03/2022
Restricted
127,646,555
01/03/2022
Unrestricted
9,559,979,042
01/03/2022
Held at DTC
9,558,973,842
01/03/2022
Float
8,725,979,042
11/15/2021
Par Value
0.0001

Good luck pushing this bloated pig.

This stock has no liquidity, what good is a stock if nobody shows interest, I'll take a loss for now but it's not my type of action at all. GLTA

This garbage is done.

Rampant dilution, garbage OTC stocks ran by crooks.

More than 70% is shorts, next squeeze should put us past $0.0057, only 15,000 shares left available to short...they used them all up, they are about to default soon.



https://iborrowdesk.com/report/AHFD

Hang in there fellas, it could happen at any moment. $AHFD

What a Joker, 6666 shares sold, ooohhh I'm scared, I think I should buy more $AHFD, LMFAO

People want instant results that are also reflected in their PPS, they forgot to look at the big picture, this is the lowest market Cap I've seen on a pink stock and this is very undervalued as of now, it just needs more exposure, peeps are all flocking on NFT and Metaverse stocks, which we all know is the newest scam trending in the OTC.

It seems that shareholders expected more action on the PR release and are disappointed with the lack of bidding.

Damn $ONPH is unreal. Major squeeze about to happen here, this one you can't even hiccup cause it's a moment's notice.

16's got out for 15's, Level II has thinned out, classic rookie move, time to blast through the ask now.

Yep, it's also where it's good to buy :)

A lot of 15's got picked up in the last 2 hours, let's hope they are in better hands.

Nice play here, it looks ready for a new HOD, IMO.

Tomorrow it will definitely ride 20's.



6 months chart, bottom is in.

ICNM SECURITY DETAILS
Share Structure
Market Cap Market Cap
16,610,533
12/31/2021
Authorized Shares
20,000,000,000
01/02/2022
Outstanding Shares
9,770,901,924
01/02/2022
Restricted
1,037,994,657
01/02/2022
Unrestricted
8,732,907,267
01/02/2022
Held at DTC
8,630,643,225
01/02/2022
Float
8,732,907,302
10/20/2021
Par Value
0.001

Going nowhere fast.

CEO Dr. Koos Message to Shareholders 12-30-2021
https://www.prnewswire.com/news-releases/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301452028.html

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

News provided by
Regen BioPharma, Inc.
Dec 30, 2021, 15:41 ET

SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP):

First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes.

When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property.

As the year progressed we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. Had I not been able to get the Company current there was a real possibility that our shareholders wouldn't be able to trade their shares and the Company's ability to raise capital would be adversely effected.

I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials.

During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. ("ONPH").

Pursuant to the terms and conditions of the licenses granted ONPH became obligated to:
(a) Pay nonrefundable fees of $55,000 and fifty thousand common shares of ONPH no later than April 20, 2021

(b) Pay royalties equal to five percent (5%) of the Net Sales (as Net Sales are defined in the Agreement) of any Licensed Products in a quarter.

Accounting for Revenues from contracts with customers and licensees is governed by Accounting Standard Codification 606 ("ASC 606") issued by the Financial Accounting Standards Board ("FASB").

ASC 606 requires that revenue be recognized as performance obligations are fulfilled. In considering the accounting for revenue generated by the licenses, the Company initially determined that the nonrefundable fees paid were consideration solely for entering into the agreement and thus should be recognized within the quarter in which they were paid.

A subsequent examination in conjunction with the Company's public accountant led us to reconsider this accounting treatment and we determined that – in order to be compliant with ASC 606- the revenue generated by the payment to the Company of the nonrefundable fees would need to be recognized over the term of the licenses. We arrived at the conclusion that entering into the agreement did not adequately meet the criteria of being "distinct within the context of the contract" from the obligation of granting the license over the term of the contract. None of the abovementioned changes the fact that $1,905,000 in cash and securities was paid to the Company during the quarter ended June 30, 2021 and this payment was nonrefundable.

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.

During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.

Sincerely,
David R. Koos
Chairman & CEO
Regen BioPharma Inc.

Regen BioPharma Inc (OTCMKTS: RGBP/RGBPP) Northbound as Biotech Grows Valuable Patent Portfolio & Grants 2 Licenses to Oncology Pharma for $1.9 Million

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-northbound-as-biotech-grows-valuable-patent-portfolio-grants-2-licenses-to-oncology-pharma-for-1-9-million/

By
Boe Rimes
December 31, 2021

Released on Sunday, January 2, 2022




Regen BioPharma Inc (OTCMKTS: RGBP) has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities.



RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.

Regen BioPharma Inc (OTCMKTS: RGBP) “pink current” operating out of San Diego, California is a publicly traded biotechnology company that was founded in 2012 focused on the immunology and immunotherapy space. Regen BioPharma is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through the Company’s patented molecular targeting approaches (BORIS), & repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). Currently RGBP has 2 investigational new drug applications (IND) filed with the FDA and 3 products in preclinical development based on the newly discovered cancer stem cell gene target



The big story on RGBP is its valuable intellectual property portfolio consisting of a large and growing number of patents. The Company’s CEO David Koos has been working hard in recent months getting all the expired Patents updated a logical step for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. Recently RGBP has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office and been issued several new patents. CEO David Koos is a highly accomplished executive who has been working in the financial markets for 3 decades. He has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.

Last month RGBP entered into an LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. The acquisition contemplated by the non-binding LOI is contingent upon several factors including, but not limited to, completion of due diligence, the completion of final negotiations, and execution of a definitive agreement. It is presently contemplated that in order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing.




To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. The activity level of these genes affects factors including how likely the cancer is to grow and spread. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. Canary Oncoceutics, Inc. is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. “Companion diagnostics in precision oncology is where the future of cancer treatment is heading. The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281”, said David Koos at the time.



On December 30 RGBP CEO David Koos wished shareholders a happy holiday season in a letter to shareholders stating: “When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer, I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property

As the year progressed, we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials. During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. (“ONPH”).

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen’s shareholders and I expect to identify a contract research organization that will help us move the Company’s intellectual propriety towards clinical trials.




RGBP has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities. RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.

Regen BioPharma Inc (OTCMKTS: RGBP/RGBPP) Northbound as Biotech Grows Valuable Patent Portfolio & Grants 2 Licenses to Oncology Pharma for $1.9 Million

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-northbound-as-biotech-grows-valuable-patent-portfolio-grants-2-licenses-to-oncology-pharma-for-1-9-million/

By
Boe Rimes
December 31, 2021

Released on Sunday, January 2, 2022




Regen BioPharma Inc (OTCMKTS: RGBP) has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities.



RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.

Regen BioPharma Inc (OTCMKTS: RGBP) “pink current” operating out of San Diego, California is a publicly traded biotechnology company that was founded in 2012 focused on the immunology and immunotherapy space. Regen BioPharma is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through the Company’s patented molecular targeting approaches (BORIS), & repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). Currently RGBP has 2 investigational new drug applications (IND) filed with the FDA and 3 products in preclinical development based on the newly discovered cancer stem cell gene target



The big story on RGBP is its valuable intellectual property portfolio consisting of a large and growing number of patents. The Company’s CEO David Koos has been working hard in recent months getting all the expired Patents updated a logical step for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. Recently RGBP has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office and been issued several new patents. CEO David Koos is a highly accomplished executive who has been working in the financial markets for 3 decades. He has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.

Last month RGBP entered into an LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. The acquisition contemplated by the non-binding LOI is contingent upon several factors including, but not limited to, completion of due diligence, the completion of final negotiations, and execution of a definitive agreement. It is presently contemplated that in order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing.




To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. The activity level of these genes affects factors including how likely the cancer is to grow and spread. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. Canary Oncoceutics, Inc. is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. “Companion diagnostics in precision oncology is where the future of cancer treatment is heading. The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281”, said David Koos at the time.



On December 30 RGBP CEO David Koos wished shareholders a happy holiday season in a letter to shareholders stating: “When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer, I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property

As the year progressed, we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials. During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. (“ONPH”).

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen’s shareholders and I expect to identify a contract research organization that will help us move the Company’s intellectual propriety towards clinical trials.




RGBP has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities. RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.

I believe every word of it. $RGBPP

I'm sure he wants his money back by now.

Regen Biopharma Inc ($RGBPP)
0.0509 ? 0.01115 (28.05%)
Volume: 2,125,639 @12/31/21 2:29:24 PM

Huge slap at the ask 609,800 shares, $30,000 buy, go big or go home. $RGBPP

Volume is almost 2 mil before 3 PM, we close above 5 cents today.

Show me 0.054, $RGBPP

That was a buy, it was at 0.00001,

More than 60% of $RGBPP have been shorted, next squeeze will take us past 25 cents.



https://iborrowdesk.com/report/RGBPP

Sweet day for $RGBP/$RGBPP, thanks for 0.037's.

Everock Inc (CE) (EVRN)
0.0001 ? 0.000099 (9900.00%)
Volume: 25,000 @12/30/21 12:23:34 PM EST

The squeeze by WSB is forcing Hedge Funds to cover all their shorts again.

A lot of junk stocks are flying since yesterday.

Nice spike followed by a huge dump, what else is new.

This baby is on fire !!! $GMEV

$RGBP/$RGBPP NEW PATENT !$!$!$!$!

https://twitter.com/Takuri333/status/1476565022214139905/photo/1

The link is bad.

RGBP Stock: The Biotech Stock To Look Out For In 2022

https://pennystocks.today/rgbp-stock-the-biotech-stock-to-look-out-for-in-2022/


Specializing in the treatment of cancer and autoimmune diseases, Regen BioPharma Inc. (OTC: RGBP) and (OTC: RGBPP) is a biotech penny stock making notable contributions to the industry and particularly the immunology and immunotherapy space. The company moved to the top of investors’ watchlists as it signed a Letter of Intent to acquire a company developing functional tests for personalized cancer drugs while reducing its debt from convertible notes by $1,023,454.

Catalysts
At the forefront of the biotech industry, Regen BioPharma’s portfolio of patents has allowed the company to make notable leaps. Earlier this year, the company obtained a license entitling it to exclusive rights for developing and marketing IP for the treatment of pancreatic cancer. This prompted a runup of 1076% for RGBPP (preferred stock) and 2723% for RGBP (common stock) in April.

The company obtained two other patents by the second quarter of 2021, the first one for using T regulatory cells in the treatment of arthritis and autoimmunity. Currently, testing this cell treatment on animals, Regen BioPharma will have a lengthy review process with the FDA before it becomes marketable. However, the global market for Rheumatoid Arthritis drugs alone was forecast to reach $36.11 billion by 2027. If this treatment proves successful, the ROI could be significant.



In October, RGBP obtained yet another patent for its “Universal Donor Checkpoint Inhibitor Silenced/Gene Edited Cord Blood Killer Cells” which covers RGBP’s invention of treatments that induce an “anticancer” response in patients. It’s therapeutic use can trigger an antitumor immune response from the body which has the potential to be revolutionary for the company.

Another patent was granted to RGBP for Antigen specific mRNA cellular cancer vaccines which could be a lucrative patent considering that mRNA is currently a leading treatment in the biotech industry. With this in mind, the company has been exploring ways to capitalize on its patents leading it to give a Scope of Work order to Biotech Research Group in October in an attempt to strategize methods of commercializing its NR2F6 intellectual property. This is important because the NR2F6 nuclear receptor was identified as a potential immune cell inhibitor that can help trigger the immune system to fight cancer as well as autoimmunity diseases and chronic inflammation.



Meanwhile, the company seems to be building on two successful deals with Oncology Pharma from earlier this year as it sets out to commercialize its research. RBGP made these agreements with Oncology Pharma giving the latter the exclusive right to develop and commercialize IP related to the treatment of cancer. In October, RGBP agreed to provide Oncology with intellectual property related to the mRNA used to treat pancreatic cancer as well. In exchange, RGBP received a fee of $55,000, and will take 5% royalties in net sales as well as 10% of all consideration from sublicensees.

At the same time, the company has been updating its filings in preparation for uplisting to the OTCQB. Its decision to opt for full reporting status has fueled speculation of a possible Big Pharma buyout which would require this level of detailed reporting. This has led some to speculate that RGBP could be an acquisition target for Oncology considering their successful relationship. But Precigen was also rumored to be a buyout candidate due to Precigen’s CEO – Helen Sabzevari – former role on RGBP’s Scientific Advisory Board. But many are hopeful that Eli Lilly is the potential target since it has maintained a very good working relationship with RGBP for over 5 years.



Beginning in 2016 with a definitive agreement allowing Regen to receive compounds from Lilly for drug discovery purposes and to exchange information of mutual interest, the two companies have since covered a lot of ground together. In 2017, Eli Lilly’s former Executive led RGBP’s newly formed Business Advisory Board. Because there is a Drug Discovery Pact between both parties, some are wondering if RGBP may be a target for the massive company.

However, RGBP is currently working to finish its strategic growth plan for the upcoming 5 years which includes diversifying the company’s operations. On that note RGBP signed a non-binding Letter of Intent (LOI) to acquire Canary Oncoceutics, Inc. which is developing an oncology diagnostic platform. This platform could be very important because it complements the existing cancer genomic testing that is used to measure how likely the cancer could grow and spread. With that in mind, Canary seems like the perfect fit to RGBP’s plans for diversifying into the in-vitro diagnostics industry. But this acquisition is dependent on a variety of factors including RGBP raising $50 million for the platform’s development.



However, RGBP’s CEO – David Koos – appears very bullish, saying “Companion diagnostics in precision oncology is where the future of cancer treatment is heading.” He went on to explain that the global cancer diagnostics market is growing rapidly – increasing from $168 billion in 2020 to a predicted valuation of $280 billion by 2028.

It also seems RGBP has been cleaning house after settling convertible notes equivalent to $1,023,454. But the company has evidently been on a campaign to pay off its debts for several months now, paying off $539,392 in other fees through the issuance of roughly 706 common shares and 23.7 million Series A Preferred shares. This appears to have nearly erased the company’s debt except for a remaining $1,340,621 in convertible notes.

*Updated December 29th, 2021

Shareholders have been reenergized with the release of RGBP’s new 10-K which shows that the company’s CEO – David Koos – is still holding Common 3.18 million common stock shares, 38% of A Preferred shares, and 26.14% of M Preferred shares as well as 100% of AA Preferred and NC preferred shares. His heavy investment in the company is definitely a bullish sign that has helped offset the dip following an announcement from Pomerantz Law Firm that it is investigating claims on behalf of Regen BioPharma, Inc.’s shareholders.

The reason for the firm’s investigation appears to be that the previously issued Balance Sheet, Statement of Operations, Statement of Shareholders Equity and Statement of Cash Flow for period ending June 30, 2021 “should not be relied upon” because it had determined that the $1,905,000 in revenue recognized from license grant to an unrelated third party should be recognized over the 15 year term of the license.



While this news shook some shareholders, most have been buoyed by the results of the company’s latest quarterly report which is unaffected by this investigation. Furthermore, Pomerantz Law Firm is not seen as a highly reputable firm having filed numerous lawsuits on similar charges.

In any case, according to RGBP’s financial document the company has $727,162 cash on hand and total assets amounting to $1.2 million. The company also recorded $171,194 in revenue but is operating at a loss of $6.7 million as is typical of biotech companies which move on binary events.

Media Sentiment
Investors like @Weezus420 are confident enough in RGBP and its potential that the dip following Pomerantz’s announcement has had little affect.


RGBP Stock Technical Analysis
RGBP stock chart
After falling roughly 32% after the release of its 10-K on the 22nd and the law firm’s announcement on the 27th, RGBP stock is trading at April’s PPS of $.01. The stock has a support near .0098 and a resistance at .0129 and .0153. The RSI was extremely oversold following the news and is still oversold at 35. Although the MACD is bullish it is approaching a bearish crossover and accumulation has rebounded from earlier overselling.

Although the stock is looking bearish at the moment, it is an excellent dip buy opportunity for investors bullish on RGBP’s treatments or buyout potential. With plans to acquire Canary Oncoceutics, Inc. RGBP has the potential to rebound if its LOI is actualized.

RGBPP Stock Technical Analysis
RGBPP stock chart
RGBPP is following a similar trend and is also trading at its support near .0314. Following a roughly 31% drop, the stock is trading at .0348 with a resistance at .0471 and .0525. As preferred stock, RGBPP has a lower float but its RSI is also oversold at 39 but with a bullish MACD and steady accumulation.

Notably, RGBPP has 437 million outstanding shares with 208 million unrestricted. This gives it a considerably lower float than RGBP stock which has 4.5 billion outstanding shares of which only 22 thousand are restricted. Both stocks have weak resistance lines which could be a bullish sign as the stock could break through with a catalyst such as its planned acquisition.

RGBP Stock Forecast
It appears that RGBP and RGBPP shareholders remain confident in the company following its 10-K filing – so much so that the law firm’s investigation has only resulted in a dip that RGBP appears poised to recover from.

RGBP’s new acquisition could be a reason to hold long-term, but as with most biotech companies the real payout comes with FDA approval and commercialization. For this reason, investors should consider the company’s pipeline of products, patents, potential, and plans when investing. Many investors are bullish on this stock’s potential which may make this dip a good investment opportunity.